New treatment for blood cancer has just been recognized

1. 10 signs appear on the body of health warning you should not be ignored
2. Bring 2 DNA in your body, which is expensive to pay for blood cancer

The US Food and Drug Administration (FDA) has approved anti-cancer drugs Besponsa, or inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia, or ALL.

B-cell ALL is a rapidly developing cancer that occurs when the bone marrow produces too many B lymphocytes, a type of white blood cell. According to estimates by the US National Cancer Institute, nearly 6,000 people in the United States are likely to be diagnosed this year, and more than 1,400 people will die from the disease.

Dr. Richard Pazdur, director of the FDA's Center for Oncology, said: "For adult patients with B-cell ALL, who have undergone initial treatment or relapse after treatment often have longevity. very low, these patients are treated according to a number of existing methods and are recently a new way of localizing the goal of treatment more precisely . '

Besponsa drugs have been evaluated in clinical studies involving 326 people with B-cell ALL, they received one or two previous treatments with different drugs. More than 35% of people assessed achieved complete remission of the disease in about eight months after taking Besponsa, compared to about 17% of people taking another drug.

Common side effects of Besponsa include low platelets, low white blood cells, infections, anemia, and fatigue and can also cause severe bleeding.

This drug label also warns of possible serious liver damage. Pregnant women or nursing mothers should not take Besponsa, FDA said.

Approval of this drug was first granted to Pfizer, based in New York City.